Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Leases (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Leases over the past 9 years, most recently at $2.4 million for Q4 2025.

  • Quarterly results put Leases at $2.4 million for Q4 2025, up 9.8% from a year ago — trailing twelve months through Dec 2025 was $2.4 million (up 9.8% YoY), and the annual figure for FY2025 was $2.4 million, up 9.8%.
  • Leases for Q4 2025 was $2.4 million at Viridian Therapeutics, Inc.\DE, up from $700000.0 in the prior quarter.
  • Over the last five years, Leases for VRDN hit a ceiling of $2.4 million in Q4 2025 and a floor of $300000.0 in Q3 2024.
  • Median Leases over the past 5 years was $1.6 million (2021), compared with a mean of $1.6 million.
  • Biggest five-year swings in Leases: soared 501.5% in 2021 and later tumbled 83.83% in 2024.
  • Viridian Therapeutics, Inc.\DE's Leases stood at $1.7 million in 2021, then decreased by 4.17% to $1.6 million in 2022, then grew by 3.73% to $1.7 million in 2023, then skyrocketed by 32.04% to $2.2 million in 2024, then grew by 9.8% to $2.4 million in 2025.
  • The last three reported values for Leases were $2.4 million (Q4 2025), $700000.0 (Q3 2025), and $2.0 million (Q2 2025) per Business Quant data.